"uuid:ID","instanceType","rationale","name","description","id","label"
"dc8373ec-b434-415d-9952-7d26a3943093","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","The main design for the study","StudyDesign_1",""
